The study analyzed that the candidiasis therapeutics pipeline comprises
approximately 22 drug candidates in different stages of development.
As per the findings of the research, most of the
candidiasis drug candidates are being developed to be administered by oral
route.
Explore Report Description at: https://www.psmarketresearch.com/market-analysis/candidiasis-therapeutics-pipeline-analysis
Matinas Biopharma Holdings, Inc. is using Cochleate
technology platform for the development of their drug candidates. The
technology platform is a lipid-crystal nano-particle targeted drug delivery
system, that offers a drug delivery solution with differentiating and
disruptive features including oral availability, multi-organ protection,
enhanced safety and targeted delivery to the site of the infection and
inflammation along with the ability to effectively penetrate the tissues.
The research found that various companies received
many designations from the U.S. Food and Drug Administration (USFDA) for the
development of candidiasis therapeutics pipeline. In May 2016, USFDA granted
the orphan drug designation to SCY-078 for the treatment of invasive candida
infections, including candidemia.
Explore Report Sample
at: https://www.psmarketresearch.com/market-analysis/candidiasis-therapeutics-pipeline-analysis/report-sample
Some of the key players
developing drugs for the treatment of candidiasis include Seren
Pharmaceuticals, Inc., SCYNEXIS, Inc., Matinas Biopharma Holdings, Inc., and
others.
No comments:
Post a Comment